Scientists Skeptical Of NIH Strategic Plan

While the agency moves to identify long-term goals, critics question the plan's feasibility as well as its fairness More than a year into the process, an atmosphere of fear, mistrust, and even hostility is clouding the formulation of the National Institutes of Health's long-range strategic plan. Although the process is alive and advancing, there are skeptics in the biomedical research community whose perceptions of what a strategic planning process is, what it should be, and what it can accom

Written byBradie Metheny
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Although the process is alive and advancing, there are skeptics in the biomedical research community whose perceptions of what a strategic planning process is, what it should be, and what it can accomplish differ from NIH's. And while an increasing number of individuals now say that the idea of a strategic plan for NIH is good, there are those who doubt that a comprehensive plan actually will evolve.

"From the beginning, there was concern about the way the strategic plan was being developed," says an official in the public affairs division of the American Society for Microbiology. "We now have our concern as to how any plan would be implemented; how will resources be allocated when there is a change in mission and no new funding?

"Of concern is the thrust for maintaining an undifferentiated strong basic research agenda and not losing that thrust in the development of the strategic ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies